Radiotherapy for Graves’ disease. The possible role of low-dose radiotherapy

Meritxell Arenas; Sebastià Sabater; Pedro Lara Jiménez; Àngels Rovirosa; Albert Biete; Victoria Linares; Montse Belles; Julià Panés

doi:10.1016/j.rpor.2016.02.001

Reports of Practical Oncology and Radiotherapy
Vol 21, No 3 (2016) Radiotherapy for Graves’ disease. The possible role of low-dose radiotherapy

Vol 21, No 3 (2016)

Review

Published online: 2016-05-01

View PDF Download PDF file

Page views 176

Article views/downloads 224

Get Citation

Connect on Social Media

Radiotherapy for Graves’ disease. The possible role of low-dose radiotherapy

Meritxell Arenas¹, Sebastià Sabater², Pedro Lara Jiménez³, Àngels Rovirosa⁴, Albert Biete⁴, Victoria Linares⁵, Montse Belles⁵, Julià Panés⁶

DOI: 10.1016/j.rpor.2016.02.001

Rep Pract Oncol Radiother 2016;21(3):213-218.

Abstract

Immunomodulatory effects of low-dose radiotherapy (LD-RT) have been used for the treatment of several benign diseases, including arthrodegenerative and inflammatory pathologies. Graves’ disease is an autoimmune disease and radiotherapy (RT) is a therapeutic option for ocular complications. The dose recommended in the clinical practice is 20[[ce:hsp sp="0.25"/]]Gy (2[[ce:hsp sp="0.25"/]]Gy/day). We hypothesized that lower doses (<10[[ce:hsp sp="0.25"/]]Gy total dose, <1[[ce:hsp sp="0.25"/]]Gy/day) could results in higher efficacy if we achieved anti-inflammatory and immunomodulatory effects of LD-RT.

We review current evidence on the effects of RT in the treatment of Graves’ disease and the possible use of LD-RT treatment strategy.

Keywords: Low-dose radiotherapyGraves’ ophthalmopathyRadiotherapy for benign disease

Article available in PDF format

View PDF Download PDF file